Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1084

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 4
Chunk 1084
---
 Regulation D promulgated thereunder in that the issuance of
securities were made to an accredited investor and did not involve a public offering. The recipients of such securities represented its
intention to acquire the securities for investment purposes only and not with a view to or for sale in connection with any distribution
thereof.

Option Grants

On July 16, 2024, the effective date of shareholder
approval to increase the number of shares authorized under the 2022 Plan, we granted a total of 504 fully vested, non-qualified options
to purchase shares of common stock at a per share exercise price of $318.00 to the following directors and in the amounts listed: (i)
Stephen Toovey (126 common stock options), (ii) Charles Allen (126 common stock options), (iii) Paul Field (126 common stock options)
and (iv) Cheryl Xu (126 common stock options).

42

On July 16, 2024, the effective date of shareholder
approval to increase the number of shares authorized under the 2022 Plan, we granted a total of 12,334 options to purchase shares of
common stock at a per share exercise price of $60.00 to Geoff Dow, our Chief Executive Officer, (5,000 common stock options), Tyrone
Miller, our Chief Financial Officer (4,000 common stock options), and Bryan Smith, an external consultant, (3,334 common stock options).
These options vest in five equal tranches on the last date of each fiscal year, with the first vesting date being December 31, 2024.

On September 26, 2024, we granted 4,167 options
to purchase shares of common stock at a per share exercise price of $6.85 to Kristen Landon, our Chief Commercial Officer, which vest
in five equal tranches on the last date of each fiscal year, with the first vesting date being December 31, 2024.

On January 2, 2025, we granted a total of 120,000
options to purchase shares of common stock at a per share exercise price of $6.55 to Geoff Dow, our Chief Executive Officer, (105,000
common stock options) and Tyrone Miller, our Chief Financial Officer (15,000 common stock options), which vest in five equal tranches.
The first tranche was fully vested on the date of grant and thereafter, the options vest on the last date of each fiscal year beginning